Prof LEUNG Yu Hung, Anskar

Prof YH Leung

Li Shu Fan Medical Foundation Professor in Haematology

  • BMedSc, PhD (CUHK), MBChB (Hons), FHKCP, FHKAM (MED), MD (HKU), FRCP (Glasgow, London, Edinburgh)
Professor Anskar Leung Yu-hung is currently a Clinical Professor in the Department of Medicine, The University of Hong Kong (HKU).  He was also the Associate Dean (Human Capital) of the Li Ka Shing Faculty of Medicine, HKU (2015 - 2018).  He graduated in 1996 with MBChB (Hons) and PhD from the Chinese University of Hong Kong and joined The University of Hong Kong as Clinical Assistant Professor in 1999.  He obtained his specialist qualification in Haematology and Haematological Oncology in 2003 and was promoted to Clinical Associate Professor and Clinical Professor in 2007 and 2012 respectively.  He has published more than 160 peer review articles and book chapters.

The research of Professor Leung focuses on the pathogenesis and treatment of acute myeloid leukaemia (AML), one of the most lethal cancers worldwide, and the study of hematopoiesis under normal and neoplastic conditions.  In particular, his team has developed zebrafish as a model organism for AML that has not only shed lights to the pathogenesis of AML but provided platform for screening therapeutic agents for AML treatment.   These efforts have been extended to primary AML samples from patients, resulting in identification of novel therapeutic regimen for specific AML subtypes that was shown to improve the outcome of these patients.   These observations have set a new paradigm for the personalised treatment of blood cancers.

At professional level, Professor Leung is currently the Honorary Consultant of Queen Mary Hospital.  He is also the Chairman of the Examination Committee, Programme Director (Haematology and Haematological Oncology) and Council member of the Hong Kong College of Physicians (HKCP) as well as the member of the Examination Board of the Royal College of Physicians (UK) (Haematology Specialist).  He is also serving in the editorial board and as reviewer in many international journals as well as being ad hoc grant reviewer for Medical Research Council (UK), Leukemia and Lymphoma Research (USA) and Austrian Academy of Sciences. 

Selected Publications
  1. Lam SY, Ho ES, He BL, Wong WW, Cher CY, Ng NK, Man CH, Gill H, Cheung AM, Ip HW, So CC, Temburini J, So CW, Ho DN, Au CH, Chan TL, Ma ES, Liang R, Kwong YL, Leung AY*.  Homoharringtonine (omacetaxine mepessucinate) as an adjunct for FLT3-ITD acute myeloid leukemia.  Sci Transl Med 8(359):359ra129.
  2. Man CH, Fung TK, Wan H, Cher CY, Fan A, Ng N, Ho C, Wan TS, Tanaka T, So EC, Kwong YL, Leung AY. Suppression of SOX7 by DNA methylation and its tumor suppressor function in acute myeloid leukemia. Blood. 2015;125(25):3928-36
  3. Shi X, He BL, Ma AC, Guo Y, Chi Y, Man CH, Zhang W, Zhang Y, Wen Z, Cheng T, Leung AY. Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish. Blood. 2015;125(19):2974-84.
  4. He BL, Shi X, Man CH, Ma AC, Ekker SC, Chow HC, So CW, Choi WW, Zhang W, Zhang Y, Leung AY*. Functions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia. Blood. 2014;123(16):2518-29. 
  5. Man CH, Lam SS, Sun MK, Chow HC, Gill H, Kwong YL, Leung AY*. A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML. Blood. 2014;123(16):2530-9.
  6. Man CH, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Cheung AM, Eaves CJ, Kwong YL, Leung AY*.  Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness with the emergence of a D835 mutation.  Blood 2012; 119(22): 5133-43. 
  7. Ma AC, Fung TK, Lin RH, Chung MI, Yang D, Ekker SC, Leung AY*.  Methionine aminopeptidase 2 is required for hematopoietic stem cell initiation and proliferation.  Blood 2011; 118(20):5448-57.  
  8. Ma AC, Chung MI, Liang R, Leung AY*. A DEAB-sensitive aldehyde dehydrogenase regulates hematopoietic stem and progenitor cells development during primitive hematopoiesis in zebrafish embryos. Leukemia. 2010; 24(12):2090-9.
  9. Ma AC, Chung MI, Liang R, Leung AY*. The role of survivin2 in primitive hematopoiesis during zebrafish development. Leukemia. 2009;23(4):712-20. 
  10. Ma AC, Ward AC, Liang R, Leung AY*.  The role of Jak2a in zebrafish hematopoiesis.  Blood 2007;110(6):1824-30.  

2016    Croucher Senior Medical Research Fellowship, The Croucher Foundation
2014    Li Shu Fan Medical Foundation Endowed Professorship in Haematology
2003    Best Dissertation Award, Hong Kong College of Physicians (Bronze)
2002    Outstanding Research Paper Award, Hong Kong College of Physicians
2000    Croucher Fellowship, The Croucher Foundation 

Grant Record
On-going external Competitive Research Grants as Principal Investigator  
Project Code/Funding Scheme Project Title/Principal Investigator/Department Approved Amount (HK$) Project Status
HKU17126117 Follistatin as a novel target and biomarker for acute myeloid leukaemia (AML) carrying internal tandem duplication (ITD) of Fms-Like Tyrosine kinase 3 (FLT3). 1,229,089 On-going
Health and Medical Research Fund
Targeting DNA damage and repair mechanism in FLT3-ITD acute myeloid leukaemia (AML) - a mechanistic and therapeutic study 1,200,000 On-going
Croucher Senior Medical Research Fellowships Develop a high throughput platform for personalized treatment of acute myeloid leukaemia 4,288,400 On-going
Health and Medical Research Fund
Establish a zebrafish model to study the molecular and clonal heterogeneity and develop personalized treatment in FLT3-ITD+ AML 1,159,608 On-going
S.K. Yee Medical Foundation
Provision of free next generation sequencing (NGS) service of prognostic and therapeutic values for patients with acute myeloid leukemia in Hong Kong 1,836,000 On-going
Collaborative Research Fund (CRF) - Group Research Project
Study of Microglia and Myeloid Leukemia in Zebrafish 350,000
Collaborative Research Fund (CRF) - Group Research Project
Development of Cell Manipulation Tools for Probing Functional Mechanism of Hematopoietic Cells: Robotics, Optical tweezers, and Hematopoiesis 1,300,000 On-going
S.K. Yee Medical Foundation
Provision of free sorafenib for patients with refractory or relapsed acute myeloid leukemia to bridge them to curative bone marrow transplantation 600,000 On-going
General Research Fund
A novel role of ADP-ribosylation factors-like 4a (arl4a) in definitive hematopoiesis 909,334 On-going

Key Offices
  • Associate Dean (Human Capital), LKS Faculty of Medicine
  • Council Member, Hong Kong College of Physicians
  • Chairman, Examination Committee, Hong Kong College of Physicians
  • Secretary, Specialty Board of Haematology and Haematological Oncology, Hong Kong College of Physicians
  • MRCP (UK) Part I Examination Board Member 

Major Editorial Board Membership
  • Blood (Since January 2018)